Pharmacogenetics in solid organ transplantation: Genes involved in mechanism of action and pharmacokinetics of immunosuppressive drugs

Pharmacogenomics

Volumn 14, Issue 9, 2013, Pages 1099-1118

  Kurzawski, Mateusz ^a   Droździk, Marek ^a  

^a POMERANIAN MEDICAL UNIVERSITY   (Poland)

Author keywords

Azathioprine; Cysclosporin A; Genetic polymorphism; Heart transplantation; Kidney transplantation; Liver transplantation; Lung transplantation; Mycophenolate mofetil; Pharmacogenetics; Tacrolimus

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; CYTOCHROME P450 2C8; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; EVEROLIMUS; GLUCOCORTICOID; GLUCURONOSYLTRANSFERASE 1A7; GLUCURONOSYLTRANSFERASE 1A8; GLUCURONOSYLTRANSFERASE 1A9; GLUCURONOSYLTRANSFERASE 2B7; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; PLACEBO; PREGNANE X RECEPTOR; RAPAMYCIN; TACROLIMUS;

ABCB1 GENE; ABCC2 GENE; ACUTE LYMPHOBLASTIC LEUKEMIA; AREA UNDER THE CURVE; BIOACCUMULATION; CROHN DISEASE; CYP2C8 GENE; CYP3A4 GENE; CYP3A5 GENE; DRUG METABOLISM; DRUG RESPONSE; GENE; GENE EXPRESSION; GENE FREQUENCY; GENE FUNCTION; GENE IDENTIFICATION; GENETIC VARIABILITY; HEART TRANSPLANTATION; HIGH RISK PATIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IMPDH1 GENE; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; LUNG TRANSPLANTATION; MAXIMUM PLASMA CONCENTRATION; NR1I2 GENE; ORGAN TRANSPLANTATION; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PHARMACOGENETICS; PREGNANE X RECEPTOR GENE; REVIEW; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; TPMT GENE; UGT1A7 GENE; UGT1A8 GENE; UGT1A9 GENE; UGT2B7 GENE;

GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ORGAN TRANSPLANTATION; PHARMACOGENETICS; POLYMORPHISM, GENETIC; TREATMENT OUTCOME; XENOBIOTICS;

EID: 84880476581     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.13.89     Document Type: Review

References (99)

1. Shiraga T, Matsuda H, Nagase K et al. Metabolism of FK506, a potent immunosuppressive agent, by cytochrome P450 3A enzymes in rat, dog and human liver microsomes. Biochem. Pharmacol. 47(4), 727-735 (1994).
2. Kuehl P, Zhang J, Lin Y et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat. Genet. 27(4), 383-391 (2001).
3. Wang D, Guo Y, Wrighton SA, Cooke GE, Sadee W. Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs. Pharmacogenomics J. 11(4), 274-286 (2011).
4. Hesselink DA, van Schaik RHN, Van Der Heiden IP et al. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin. Pharmacol. Ther. 74(3), 245-254 (2003).
5. Haufroid V, Mourad M, Van Kerckhove V et al. The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics 14(3), 147-154 (2004
6. Tavira B, Garcia EC, Diaz-Corte C et al. Pharmacogenetics of tacrolimus after renal transplantation: Analysis of polymorphisms in genes encoding 16 drug metabolizing enzymes. Clin. Chem. Lab. Med. 49(5), 825-833 (2011).
7. Zhao W, Fakhoury M, Baudouin V et al. Population pharmacokinetics and pharmacogenetics of once daily prolonged-release formulation of tacrolimus in pediatric and adolescent kidney transplant recipients. Eur. J. Clin. Pharmacol. 69(2), 189-195 (2013).
8. Garcia-Roca P, Medeiros M, Reyes H et al. CYP3A5 polymorphism in Mexican renal transplant recipients and its association with tacrolimus dosing. Arch. Med. Res. 43(4), 283-287 (2012).
9. Cho JH, Yoon YD, Park JY et al. Impact of cytochrome P450 3A and ATP-binding cassette subfamily B member 1 polymorphisms on tacrolimus dose-adjusted trough concentrations among Korean renal transplant recipients. Transplant. Proc. 44(1), 109-114 (2012).
10. Niioka T, Satoh S, Kagaya H et al. Comparison of pharmacokinetics and pharmacogenetics of once- and twice-daily tacrolimus in the early stage after renal transplantation. Transplantation 94(10), 1013-1019 (2012).
11. Glowacki F, Lionet A, Hammelin JP et al. Influence of cytochrome P450 3A5 (CYP3A5) genetic polymorphism on the pharmacokinetics of the prolonged-release, once-daily formulation of tacrolimus in stable renal transplant recipients. Clin. Pharmacokinet. 50(7), 451-459 (2011).
12. Hashimoto H, Toide K, Kitamura R et al. Gene structure of CYP3A4, an adult-specific form of cytochrome P450 in human livers, and its transcriptional control. Eur. J. Biochem. 218(2), 585-595 (1993).
13. Gervasini G, Garcia M, Macias RM, Cubero JJ, Caravaca F, Benitez J. Impact of genetic polymorphisms on tacrolimus pharmacokinetics and the clinical outcome of renal transplantation. Transplant. Int. 25(4), 471-480 (2012).
14. Elens L, van Schaik RH, Panin N et al. Effect of a new functional CYP3A4 polymorphism on calcineurin inhibitors' dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenomics 12(10), 1383-1396 (2011). n Evaluates the impact of a novel CYP3A4*22 allele on tacrolimus (TAC) dosing and presents its significance as a marker
15. Saeki T, Ueda K, Tanigawara Y, Hori R, Komano T. Human P-glycoprotein transports cyclosporin A and FK506. J. Biol. Chem. 268(9), 6077-6080 (1993).
16. Kimchi-Sarfaty C, Oh JM, Kim IW et al. A 'silent' polymorphism in the MDR1 gene changes substrate specificity. Science 315(5811), 525-528 (2007).
17. Li D, Gui R, Li J, Huang Z, Nie XM. Tacrolimus dosing in Chinese renal transplant patients is related to MDR1 gene C3435T polymorphisms. Transplant. Proc. 38(9), 2850-2852 (2006).
18. Akbas SH, Bilgen T, Keser I et al. The effect of MDR1 (ABCB1) polymorphism on the pharmacokinetic of tacrolimus in Turkish renal transplant recipients. Transplant. Proc. 38(5), 1290-1292 (2006).
19. Haufroid V, Mourad M, Van Kerckhove V et al. The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogeneticss 14(3), 147-154 (2004).
20. Kuypers DR, Naesens M, de Jonge H, Lerut E, Verbeke K, Vanrenterghem Y. Tacrolimus dose requirements and CYP3A5 genotype and the development of calcineurin inhibitor-associated nephrotoxicity in renal allograft recipients. Ther. Drug Monit. 32(4), 394-404 (2010).
21. Li Y, Hu X, Cai B et al. Meta-analysis of the effect of MDR1 C3435 polymorphism on tacrolimus pharmacokinetics in renal transplant recipients. Transplant. Immunol. 27(1), 12-18 (2012).
22. de Jonge H, Metalidis C, Naesens M, Lambrechts D, Kuypers DR. The P450 oxidoreductas.e. *28 SNP is associated with low initial tacrolimus exposure and increased dose requirements in CYP3A5-expressing renal recipients. Pharmacogenomics 12(9), 1281-1291 (2011).
23. Boivin AA, Cardinal H, Barama A et al. Influence of SLCO1B3 genetic variations on tacrolimus pharmacokinetics in renal transplant recipients. Drug. Metab. Pharmacokinet. doi:http://dx.doi.org/10.2133/ dmpk.DMPK-12-SH-093 (2012) (Epub ahead of print).
24. Shitara Y, Takeuchi K, Nagamatsu Y, Wada S, Sugiyama Y, Horie T. Long-lasting inhibitory effects of cyclosporin A, but not tacrolimus, on OATP1B1- and OATP1B3-mediated uptake. Drug. Metab. Pharmacokinet. 27(4), 368-378 (2012).
25. Birdwell KA, Grady B, Choi L et al. The use of a DNA biobank linked to electronic medical records to characterize pharmacogenomic predictors of tacrolimus dose requirement in kidney transplant recipients. Pharmacogenet. Genomics 22(1), 32-42 (2012)
26. Thervet E, Loriot MA, Barbier S et al. Optimization of initial tacrolimus dose using pharmacogenetic testing. Clin. Pharmacol. Ther. 87(6), 721-726 (2010). n Prospective study presenting a CYP3A5 genotype-based algorithm and its advantage over regular algorithms
27. Passey C, Birnbaum AK, Brundage RC, Oetting WS, Israni AK, Jacobson PA. Dosing equation for tacrolimus using genetic variants and clinical factors. Br. J. Clin. Pharmacol. 72(6), 948-957 (2011).
28. Elens L, Hesselink DA, van Schaik RH, van Gelder T. The CYP3A4*22 allele affects the predictive value of a pharmacogenetic algorithm predicting tacrolimus predose concentrations. Br. J. Clin. Pharmacol. (2012).
29. Quteineh L, Verstuyft C, Furlan V et al. Influence of CYP3A5 genetic polymorphism on tacrolimus daily dose requirements and acute rejection in renal graft recipients. Basic Clin. Pharmacol. Toxicol. 103(6), 546-552 (2008).
30. Min SI, Kim SY, Ahn SH et al. CYP3A5 *1 allele: Impacts on early acute rejection and graft function in tacrolimus-based renal transplant recipients. Transplantation 90(12), 1394-1400 (2010).
31. Miura Y, Satoh S, Saito M et al. Factors increasing quantitative interstitial fibrosis from 0 hr to 1 year in living kidney transplant patients receiving tacrolimus. Transplantation 91(1), 78-85 (2011).
32. Naesens M, Lerut E, de Jonge H et al. Donor age and renal P-glycoprotein expression associate with chronic histological damage in renal allografts. J. Am. Soc. Nephrol. 20(11), 2468-2480 (2009).
33. Miao LY, Huang CR, Hou JQ, Qian MY. Association study of ABCB1 and CYP3A5 gene polymorphisms with sirolimus trough concentration and dose requirements in Chinese renal transplant recipients. Biopharm. Drug Dispos. 29(1), 1-5 (2008).
34. Sam WJ, Chamberlain CE, Lee SJ et al. Associations of ABCB1 3435C > T and IL- 10-1082G > a polymorphisms with long-term sirolimus dose requirements in renal transplant patients. Transplantation 92(12), 1342-1347 (2011).
35. Mourad M, Mourad G, Wallemacq P et al. Sirolimus and tacrolimus trough concentrations and dose requirements after kidney transplantation in relation to CYP3A5 and MDR1 polymorphisms and steroids. Transplantation 80(7), 977-984 (2005).
36. Moes D, Press RR, den Hartigh J, Van Der Straaten T, de Fijter JW, Guchelaar HJ. Population pharmacokinetics and pharmacogenetics of everolimus in renal transplant patients. Clin. Pharmacokinet. 51(7), 467-480 (2012).
37. Tett SE, Saint-Marcoux F, Staatz CE et al. Mycophenolate, clinical pharmacokinetics, formulations, and methods for assessing drug exposure. Transplant. Rev. (Orlando) 25(2), 47-57 (2011).
38. Basu NK, Kole L, Kubota S, Owens IS. Human UDP-glucuronosyltransferases show atypical metabolism of mycophenolic acid and inhibition by curcumin. Drug. Metab. Dispos. 32(7), 768-773 (2004).
39. Picard N, Ratanasavanh D, Premaud A, Le Meur Y, Marquet P. Identification of the UDP-glucuronosyltransferase isoforms involved in mycophenolic acid phase II metabolism. Drug Metab. Dispos. 33(1), 139-146 (2005).
40. Kuypers DR, de Jonge H, Naesens M et al. Current target ranges of mycophenolic acid exposure and drug-related adverse events: A 5 year, open-label, prospective, clinical follow-up study in renal allograft recipients. Clin. Ther. 30(4), 673-683 (2008).
41. van Schaik RHN, van Agteren M, de Fijter JW et al. UGT1A9 -275T>A/-2152C>T Polymorphisms correlate with low MPA exposure and acute rejection in MMF/tacrolimus-treated kidney transplant patients. Clin. Pharmacol. Ther. 86(3), 319-327 (2009). n Study on mycophenolate mofetil pharmacogenetics with a sufficient sample size, revealing significant associations with drug pharmacokinetics and acute rejection risk
42. Sanchez-Fructuoso AI, Maestro ML, Calvo N et al. The prevalence of uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) gene promoter region single-nucleotide polymorphisms T-275A and C-2152T and its influence on mycophenolic acid pharmacokinetics in stable renal transplant patients. Transplant. Proc. 41(6), 2313-2316 (2009).
43. Johnson LA, Oetting WS, Basu S, Prausa S, Matas A, Jacobson PA. Pharmacogenetic effect of the UGT polymorphisms on mycophenolate is modified by calcineurin inhibitors. Eur. J. Clin. Pharmacol. 64(11), 1047-1056 (2008).
44. Kobayashi M, Saitoh H, Tadano K, Takahashi Y, Hirano T. Cyclosporin A, but not tacrolimus, inhibits the biliary excretion of mycophenolic acid glucuronide possibly mediated by multidrug resistance-associated protein 2 in rats. J. Pharmacol. Exp. Ther. 309(3), 1029-1035 (2004).
45. Miura M, Kagaya H, Satoh S et al. Influence of drug transporters and UGT polymorphisms on pharmacokinetics of phenolic glucuronide metabolite of mycophenolic acid in Japanese renal transplant recipients. Ther. Drug. Monit. 30(5), 559-564 (2008).
46. Baldelli S, Merlini S, Perico N et al. C-440T/ T-331C polymorphisms in the UGT1A9 gene affect the pharmacokinetics of mycophenolic acid in kidney transplantation. Pharmacogenomics 8(9), 1127-1141 (2007).
47. Lloberas N, Torras J, Cruzado JM et al. Influence of MRP2 on MPA pharmacokinetics in renal transplant recipients-results of the pharmacogenomic substudy within the symphony study. Nephrol. Dial. Transplant. 26(11), 3784-3793 (2011).
48. Shipkova M, Armstrong VW, Oellerich M, Wieland E. Acyl glucuronide drug metabolites: Toxicological and analytical implications. Ther. Drug Monit. 25(1), 1-16 (2003).
49. Naesens M, Kuypers DR, Verbeke K, Vanrenterghem Y. Multidrug resistance protein 2 genetic polymorphisms influence mycophenolic acid exposure in renal allograft recipients. Transplantation 82(8), 1074-1084 (2006).
50. Woillard JB, Rerolle JP, Picard N et al. Risk of diarrhoea in a long-term cohort of renal transplant patients given mycophenolate mofetil: The significant role of the UGT1A8 2 variant allele. Br. J. Clin. Pharmacol. 69(6), 675-683 (2010).
51. Miura M, Satoh S, Inoue K et al. Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Eur. J. Clin. Pharmacol. 63(12), 1161-1169 (2007).
52. Wang J, Yang JW, Zeevi A et al. IMPDH1 gene polymorphisms and association with acute rejection in renal transplant patients. Clin. Pharmacol. Ther. 83(5), 711-717 (2008).
53. Kagaya H, Miura M, Saito M, Habuchi T, Satoh S. Correlation of IMPDH1 gene polymorphisms with subclinical acute rejection and mycophenolic acid exposure parameters on day 28 after renal transplantation. Basic Clin. Pharmacol. Toxicol. 107(2), 631-636 (2010).
54. Grinyo J, Vanrenterghem Y, Nashan B et al. Association of four DNA polymorphisms with acute rejection after kidney transplantation. Transpl. Int. 21(9), 879-891 (2008).
55. Sombogaard F, van Schaik RH, Mathot RA et al. Interpatient variability in IMPDH activity in MMF-treated renal transplant patients is correlated with IMPDH type II 3757T > C polymorphism. Pharmacogenet. Genomics 19(8), 626-634 (2009).
56. Halloran P, Mathew T, Tomlanovich S, Groth C, Hooftman L, Barker C. Mycophenolate mofetil in renal allograft recipients: A pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. The International Mycophenolate Mofetil Renal Transplant Study Groups. Transplantation 63(1), 39-47 (1997).
57. Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: Monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am. J. Hum.Genet. 32(5), 651-662 (1980).
58. Kurzawski M, Dziewanowski K, Ciechanowski K, Drozdzik M. Severe azathioprine-induced myelotoxicity in a kidney transplant patient with thiopurine S-methyltransferase-deficient genotype (TPMT*3A/*3C). Transpl. Int. 18(5), 623-625 (2005).
59. Budhiraja P, Popovtzer M. Azathioprine-related myelosuppression in a patient homozygous for TPMT*3A. Nat. Rev. Nephrol. 7(8), 478-484 (2011).
60. Yates CR, Krynetski EY, Loennechen T et al. Molecular diagnosis of thiopurine S-methyltransferase deficiency: Genetic basis for azathioprine and mercaptopurine intolerance. Ann. Intern. Med. 126(8), 608-614 (1997).
61. Stocco G, Franca R, Verzegnassi F, Londero M, Rabusin M, Decorti G. Multilocus genotypes of relevance for drug metabolizing enzymes and therapy with thiopurines in patients with acute lymphoblastic leukemia. Front. Genet. 3, 309 (2012).
62. Relling MV, Gardner EE, Sandborn WJ et al. Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clin. Pharmacol. Ther. 89(3), 387-391 (2011).
63. Formea CM, Myers-Huentelman H, Wu R et al. Thiopurine S-methyltransferase genotype predicts azathioprine-induced myelotoxicity in kidney transplant recipients. Am. J. Transplant. 4(11), 1810-1817 (2004).
64. Kurzawski M, Dziewanowski K, Gawronska- Szklarz B, Domanski L, Drozdzik M. The impact of thiopurine S-methyltransferase polymorphism on azathioprine-induced myelotoxicity in renal transplant recipients. Ther. Drug Monit. 27(4), 435-441 (2005).
65. Kurzawski M, Dziewanowski K, Lener A, Drozdzik M. TPMT but not ITPA gene polymorphism influences the risk of azathioprine intolerance in renal transplant recipients. Eur. J. Clin. Pharmacol. 65(5), 533-540 (2009).
66. Xin HW, Xiong H, Wu XC, Li Q, Xiong L, Yu AR. Relationships between thiopurine S-methyltransferase polymorphism and azathioprine-related adverse drug reactions in Chinese renal transplant recipients. Eur. J. Clin. Pharmacol. 65(3), 249-255 (2009).
67. Vannaprasaht S, Angsuthum S, Avihingsanon Y et al. Impact of the heterozygous TPMT*1/*3C genotype on azathioprine-induced myelosuppression in kidney transplant recipients in Thailand. Clin. Ther. 31(7), 1524-1533 (2009).
68. Fabre MA, Jones DC, Bunce M et al. The impact of thiopurine S-methyltransferase polymorphisms on azathioprine dose 1 year after renal transplantation. Transpl. Int. 17(9), 531-539 (2004).
69. Song DK, Zhao J, Zhang LR. TPMT genotype and its clinical implication in renal transplant recipients with azathioprine treatment. J. Clin. Pharm. Ther. 31(6), 627-635 (2006).
70. von Ahsen N, Oellerich M, Armstrong VW. Characterization of the inosine triphosphatase (ITPA) gene: Haplotype structure, haplotype-phenotype correlation and promoter function. Ther. Drug Monit. 30(1), 16-22 (2008).
71. van Dieren JM, Hansen BE, Kuipers EJ, Nieuwenhuis EE, Van Der Woude CJ. Meta-analysis: Inosine triphosphate pyrophosphatase polymorphisms and thiopurine toxicity in the treatment of inflammatory bowel disease. Aliment. Pharmacol. Ther. 26(5), 643-652 (2007).
72. Xiong H, Xin HW, Wu XC, Li Q, Xiong L, Yu AR. Association between inosine triphosphate pyrophosphohydrolase deficiency and azathioprine-related adverse drug reactions in the Chinese kidney transplant recipients. Fundam. Clin. Pharmacol. 24(3), 393-400 (2010).
73. Kurzawski M, Dziewanowski K, Safranow K, Drozdzik M. Polymorphism of genes involved in purine metabolism (XDH, AOX1, MOCOS) in kidney transplant recipients receiving azathioprine. Ther. Drug Monit. 34(3), 266-274 (2012).
74. Miura M, Satoh S, Inoue K et al. Influence of CYP3A5, ABCB1 and NR1I2 polymorphisms on prednisolone pharmacokinetics in renal transplant recipients. Steroids 73(11), 1052-1059 (2008).
75. Wiesner RH, Fung JJ. Present state of immunosuppressive therapy in liver transplant recipients. Liver Transpl. 17(Suppl. 3), S1-S9 (2011).
76. Tisone G, Orlando G, Angelico M. Operational tolerance in clinical liver transplantation: Emerging developments. Transpl. Immunol. 17(2), 108-113 (2007).
77. Shi Y, Li Y, Tang J et al. Influence of CYP3A4, CYP3A5 and MDR-1 polymorphisms on tacrolimus pharmacokinetics and early renal dysfunction in liver transplant recipients. Gene 512(2), 226-231 (2013).
78. Yu XB, Xie HY, Wei BJ et al. Association of MDR1 gene SNPs and haplotypes with the tacrolimus dose requirements in Han Chinese liver transplant recipients. PLoS ONE 6(11), e25933 (2011).
79. Uesugi M, Masuda S, Katsura T, Oike F, Takada Y, Inui KI. Effect of intestinal CYP3A5 on postoperative tacrolimus trough levels in living-donor liver transplant recipients. Pharmacogenet. Genomics 16(2), 119-127 (2006). n Addresses an important issue in liver transplantation: Both patient's and donor's genotype may influence TAC pharmacokinetics
80. Fukudo M, Yano I, Yoshimura A et al. Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients. Pharmacogenet. Genomics 18(5), 413-423 (2008).
81. Muraki Y, Usui M, Isaji S et al. Impact of CYP3A5 genotype of recipients as well as donors on the tacrolimus pharmacokinetics and infectious complications after living-donor liver transplantation for Japanese adult recipients. Ann. Transplant. 16(4), 55-62 (2011).
82. Provenzani A, Notarbartolo M, Labbozzetta M et al. The effect of CYP3A5 and ABCB1 single nucleotide polymorphisms on tacrolimus dose requirements in Caucasian liver transplant patients. Ann. Transplant. 14(1), 23-31 (2009).
83. Barrera-Pulido L, Aguilera-Garcia I, Docobo- Perez F et al. Clinical relevance and prevalence of polymorphisms in CYP3A5 and MDR1 genes that encode tacrolimus biotransformation enzymes in liver transplant recipients. Transplant. Proc. 40(9), 2949-2951 (2008).
84. Bonhomme-Faivre L, Devocelle A, Saliba F et al. MDR-1 C3435T polymorphism influences cyclosporine A dose requirement in liver-transplant recipients. Transplantation 78(1), 21-25 (2004).
85. Hebert MF, Dowling AL, Gierwatowski C et al. Association between ABCB1 (multidrug resistance transporter) genotype and post-liver transplantation renal dysfunction in patients receiving calcineurin inhibitors. Pharmacogenetics 13(11), 661-674 (2003).
86. Breen DP, Marinaki AM, Arenas M, Hayes PC. Pharmacogenetic association with adverse drug reactions to azathioprine immunosuppressive therapy following liver transplantation. Liver Transplant. 11(7), 826-833 (2005).
87. Buster EH, van Vuuren HJ, Zondervan PE, Metselaar HJ, Tilanus HW, de Man RA. Thiopurine-methyltransferase and inosine triphosphate pyrophosphatase polymorphism in a liver transplant recipient developing nodular regenerative hyperplasia on low-dose azathioprine. Eur. J. Gastroenterol. Hepatol. 20(1), 68-72 (2008).
88. Kniepeiss D, Renner W, Trummer O et al. The role of CYP3A5 genotypes in dose requirements of tacrolimus and everolimus after heart transplantation. Clin. Transplant. 25(1), 146-150 (2011).
89. Diaz-Molina B, Tavira B, Lambert JL, Bernardo MJ, Alvarez V, Coto E. Effect of CYP3A5, CYP3A4, and ABCB1 genotypes as determinants of tacrolimus dose and clinical outcomes after heart transplantation. Transplant. Proc. 44(9), 2635-2638 (2012).
90. Taegtmeyer AB, Breen JB, Smith J et al. ATP-binding cassette subfamily B member 1 polymorphisms do not determine cyclosporin exposure, acute rejection or nephrotoxicity after heart transplantation. Transplantation 89(1), 75-82 (2010).
91. Chowbay B, Cumaraswamy S, Cheung YB, Zhou Q, Lee EJ. Genetic polymorphisms in MDR1 and CYP3A4 genes in Asians and the influence of MDR1 haplotypes on cyclosporin disposition in heart transplant recipients. Pharmacogenetics 13(2), 89-95 (2003).
92. Hesselink DA, van Gelder T, van Schaik RH et al. Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic polymorphisms in the MDR-1, CYP3A4, and CYP3A5 genes. Clin. Pharmacol. Ther. 76(6), 545-556 (2004).
93. Ting LS, Benoit-Biancamano MO, Bernard O, Riggs KW, Guillemette C, Ensom MH. Pharmacogenetic impact of UDP-glucuronosyltransferase metabolic pathway and multidrug resistance-associated protein 2 transport pathway on mycophenolic acid in thoracic transplant recipients: An exploratory study. Pharmacotherapy 30(11), 1097-1108 (2010).
94. Ohmann EL, Burckart GJ, Brooks MM et al. Genetic polymorphisms influence mycophenolate mofetil-related adverse events in pediatric heart transplant patients. J. Heart Lung Transplant. 29(5), 509-516 (2010).
95. Ohmann EL, Burckart GJ, Chen Y et al. Inosine 5′-monophosphate dehydrogenase 1 haplotypes and association with mycophenolate mofetil gastrointestinal intolerance in pediatric heart transplant patients. Pediatr. Transplant. 14(7), 891-895 (2010).
96. Sebbag L, Boucher P, Davelu P et al. Thiopurine S-methyltransferase gene polymorphism is predictive of azathioprine-induced myelosuppression in heart transplant recipient. Transplantation 69(7), 1524-1527 (2000).
97. Zheng HX, Zeevi A, Schuetz E et al. Tacrolimus dosing in adult lung transplant patients is related to cytochrome P4503A5 gene polymorphism. J. Clin. Pharmacol. 44(2), 135-140 (2004).
98. Wang J, Zeevi A, McCurry K et al. Impact of ABCB1 (MDR1) haplotypes on tacrolimus dosing in adult lung transplant patients who are CYP3A5*3/ *3 nonexpressors. Transplant. Immunol. 15(3), 235-240 (2006).
99. Zheng HX, Zeevi A, McCurry K et al. The impact of pharmacogenomic factors on acute persistent rejection in adult lung transplant patients. Transplant. Immunol. 14(1), 37-42 (2005